When we play a round of golf or spend an afternoon on our knees in the garden or just take a nice long walk, we are celebrating our freedom.
AprèsFlex has been giving people back their freedom for almost a decade, by delivering joint comfort and flexibility from 100 mg dose that starts to work in only 5 days.
Around the world, people have turned to AprèsFlex more than a billion times as a drug-free approach to joint comfort. They trust the science. Trust the quality. And trust the experience.
AprèsFlex can be an important part of your active/sports nutrition formulations. Inflammation from exercise has similarities to the type of inflammation that occurs with the aging process. AprèsFlex can help you get your customers back into the gym faster – and happier.
AprèsFlex is one of the world’s best-selling joint health ingredients – with multiple clinical studies that demonstrate efficacy starting at 5 days – with a low dose. Clinical studies have shown a 20% reduction in pain scores at 5 days and p to a 70% reduction in 90 days.
Today’s seniors travel more, play more and do more than ever. AprèsFlex can help them get moving and keep moving. They’ll notice the difference quickly and come back for more.
Mobility and freedom from discomfort are critical to the kind of exercise we need to maintain a healthy weight. AprèsFlex can help your customers succeed in achieving their weight management goals by giving them the freedom to workout.
Clinical studies conducted with AprèsFlex show dramatic improvements in joint comfort. A 2014 clinical trial with AprèsFlex showed a nearly 20% reduction in pain scores over baseline at 5 days and a 50% reduction in pain scores at 30 days. A previous, similar study with AprèsFlex showed a 70% reduction in pain scores at 90 days.
Beyond joint comfort and flexibility improvements, AprèsFlex also positively impacts biological markers associated with joint health and inflammation, including TNFa, CRP, and IL-6. It was also shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, collagen and connective tissues.
AprèsFlex is derived from Boswellia serrata gum resin and contains 20% AKBA. It was developed based upon a 1st generation clinically studied Boswellia serrata extract that provided 30% Acetyl-11-keto-β-boswellic acid (AKBA) along with other boswellic acids The bioavailability of AKBA from AprèsFlex was found to be significantly higher in comparison with that of other commercially available Boswellia extracts.
The starting point for AprèsFlex – Boswellia serrata – is a plant that produces Indian frankincense. It is also known as Indian oli-banum, Salai guggul, and Sallaki in Sanskrit. The plant is native to much of India and the Punjab region that extends into Pakistan. In the last five years, PLT partner Laila Nutra has planted over 100,000 frankincense trees in India. Laila and PLT are committed to the safety and fair treatment of the people who harvest AprèsFlex. We want to support the long-term health and well-being of the tribal culture and the natural environment upon which it relies.
Every batch of the AprèsFlex harvest is assigned a specific batch number and each batch of finished product is traceable to a specific region and set of trees. AprèsFlex is tested and must comply with predefined specifications for different parameters at different stages of product manufacturing – from raw materials to finished product. Quality is monitored by a multi-disciplinary organization with dedicated departments for taxonomy (botanical Identification), raw material analysis, chemical analysis, microbiology and more.
Sales Collateral
PLT has a broad range of joint health solutions that can work in almost any type of product you’re making.
Clinical Research